Urgent Alert: BV Is Sexually Transmitted, and Most Treatments Ignore the Root Cause

 

Urgent Alert: BV Is Sexually Transmitted, and Most Treatments Ignore the Root Cause

BV Is an STD, and We’ve Been Treating It Wrong for Years

For years, bacterial vaginosis (BV) has been misunderstood and mistreated. While traditionally considered an imbalance in the vaginal microbiome, groundbreaking research now confirms that BV is actually a sexually transmitted infection (STI). This revelation could revolutionize treatment approaches and significantly reduce BV recurrence rates.

BV Identified as an STI, Changing the Game

A major study has confirmed that bacterial vaginosis (BV) is an STI, challenging long-held beliefs about its origins and treatment. Affecting nearly one in three women globally, BV has been linked to infertility, premature birth, and increased susceptibility to other infections.

Researchers from Monash University and Alfred Health at the Melbourne Sexual Health Centre published their findings in the New England Journal of Medicine, shedding new light on why traditional treatments fail. Current approaches focus on correcting vaginal microbiome imbalances, yet more than half of women experience a BV recurrence within three months of completing antibiotic treatment.

Groundbreaking Trial Proves Partner Treatment Works

A clinical trial involving 164 monogamous couples revealed that treating both partners simultaneously led to significantly higher BV cure rates. Traditionally, treatment has focused solely on the affected woman, ignoring the role male partners play in BV transmission and persistence.

The trial was stopped early due to overwhelmingly positive results—partner treatment reduced BV recurrence rates by half. This suggests that failure to treat male partners may be a key reason why BV frequently returns, frustrating millions of women worldwide.

A Simple, Short Treatment With a Big Impact

“This successful intervention is relatively cheap and short and has the potential to improve BV cure rates and open up new prevention strategies,” says Professor Catriona Bradshaw, lead researcher on the study.

Women in the study received standard oral antibiotics, while male partners were randomly assigned either to receive both oral antibiotics and a topical antibiotic cream or to a control group where only the woman was treated. After just one week of treatment, couples were monitored for 12 weeks to assess BV cure rates.

BV’s Connection to Other STIs

Beyond being a sexually transmitted infection, BV also increases the risk of contracting other STIs such as chlamydia and gonorrhea. According to Dr. Lenka Vodstrcil, one of the study’s lead authors, BV shares an incubation period and risk factors similar to those of other STIs, such as changes in sexual partners and inconsistent condom use.

While previous studies showed that men may harbor BV-related bacteria on the penile skin and within the urethra, they failed to show improved cure rates when men were treated. This led researchers to mistakenly conclude that BV was not sexually transmitted.

Why Earlier Studies Got It Wrong

The failure of past research to prove BV’s sexual transmission was largely due to incomplete treatment protocols. Previous trials did not use a combination of oral and topical antibiotics, meaning bacteria remained on the penile skin, leading to reinfection.

“Part of the difficulty in establishing BV as an STI is that we still don’t know precisely which bacteria cause it,” explains Professor Bradshaw. However, advances in genomic sequencing are helping scientists identify the precise bacterial species responsible for BV transmission.

Changing Treatment Guidelines for BV

The findings of this study have already prompted the Melbourne Sexual Health Centre to update its clinical practices. To ensure accessibility, researchers have also launched a dedicated website for health professionals and the public, providing clear guidelines on BV partner treatment.

Although national and international guidelines take time to update, this new evidence highlights the urgent need to change BV treatment approaches. By recognizing BV as an STI, health professionals can finally address the root cause of its high recurrence rates.

Final Thoughts: The Future of BV Treatment

The confirmation that BV is an STI marks a critical turning point in women’s sexual health. Instead of temporary fixes, medical professionals can now adopt comprehensive treatment strategies that prevent reinfection and improve long-term health outcomes. With partner treatment proving effective, a future where BV recurrence rates are dramatically reduced is finally within reach.

By staying informed and advocating for science-backed treatments, women can take control of their sexual and reproductive health—without the frustration of persistent BV infections.